- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04788524
Neural Correlates of Stress and Perceived Control in Adolescent Depression
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Participants in this research will include 40 female adolescents, aged 14-18, with Major Depressive Disorder (MDD) and 40 healthy adolescents from the greater Boston area by Dr. Emily Belleau, at McLean Hospital's Center for Depression, Anxiety and Stress Research.
The study will include four sessions:
- A clinical diagnostic interview as well as filling out a series of questionnaires and assessments.
- The second session will include a functional magnetic resonance imaging (fMRI) brain scan to be conducted at the McLean Hospital Imaging Center. Participants will be asked to respond to surveys on their cell phone in the week following the fMRI brain scan.
- The third session will include a diagnostic interview, assessments, and questionnaires to be completed three-months after the fMRI brain scan. Participants will be asked to complete surveys on their cell phone during the week following this three month follow-up session.
- The fourth session will include a diagnostic interview, assessments, and questionnaires to be completed six-months after the fMRI brain scan. Participants will be asked to complete surveys on their cell phone during the week following this six month follow-up session.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Emily L Belleau, PhD
- Telefonnummer: 6178554245
- E-post: ebelleau@mclean.harvard.edu
Studiesteder
-
-
Massachusetts
-
Belmont, Massachusetts, Forente stater, 02478
- Rekruttering
- McLean Hospital
-
Ta kontakt med:
- Emily L Belleau, PhD
- Telefonnummer: 617-855-4245
- E-post: ebelleau@mclean.harvard.edu
-
Hovedetterforsker:
- Emily L Belleau, PhD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Inclusion Criteria: All Participants
- Females of all ethnic origins See Section: Inclusion of Women and Minorities);
- Ages 14-18 (See Section: Inclusion of Children);
- Written informed assent/consent from adolescent and parent/guardian (if under age 18);
- English as a first language or English fluency;
- Right handed111;
- Personal cell-phone (for Ecological Momentary Assessment [EMA]) 7 All participants will be in the follicular phase of their menstrual cycle when completing the functional magnetic resonance imaging (fMRI) study session
Inclusion Criteria: MDD Sample
- Meet Diagnostic Statistical Manual-5th edition (DSM-5) diagnostic criteria for major depressive disorder (as diagnosed with the KSADS)
- Absence of any psychotropic medications for at least 2 weeks (6 weeks for fluoxetine; 6 months for neuroleptics; 2 weeks for benzodiazepines; 2 weeks for any other antidepressants);
Inclusion Criteria: Healthy Control (HC) Sample
- No history or current diagnosis of any DSM-5 psychiatric or substance/alcohol-related disorder (as diagnosed with the KSADS)
- No first-degree relatives with a history of depression, bipolar disorder, or psychosis
Exclusion Criteria:
Exclusion Criteria: All Participants
- History of head trauma with loss of consciousness;
- History of seizure disorder;
- Serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease;
- History of cocaine or stimulant use (e.g., amphetamine, cocaine, methamphetamine);
- History of use of dopaminergic drugs (including methylphenidate);
- Use of hormonal replacement therapy, anabolic steroids, or hormonal contraception;
- Clinical or laboratory evidence of hypothyroidism;
- Systemic medical or neurological illness that could impact fMRI measures of cerebral blood flow;
- Failure to meet standard exclusion criteria for fMRI scanning (e.g., claustrophobia, cardiac pacemakers, neural pacemakers, surgically implanted metal devices, cochlear implants, metal braces, or other metal objects in the body);
- Pregnancy
- Testing positive on a drug test on the day of the scan which testis for stimulants, marijuana, barbiturates, benzodiazepine, buprenorphine, 3,4-Methyl enedioxy methamphetamine (MDMA), methadone, opiates, oxycodone, phencyclidine;
- History of electroconvulsive therapy
- Participants with suicidal ideation where study participation is deemed unsafe by the study clinician;
Additional Exclusion Criteria: Major Depressive Disorder (MDD) Sample
1. Major depressive disorder diagnosis secondary to another disorder (selected comorbid anxiety disorders such as generalized anxiety disorder, specific phobia, and social anxiety disorders are allowed if they are secondary to MDD)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Computer Task Manipulation
Participants will complete computer tasks while undergoing an fMRI brain scan
|
Participants will complete computer tasks.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Blood-Oxygen-Level-Dependent Imaging (BOLD) activation of the ventral striatum and ventral medial prefrontal cortex
Tidsramme: 1.5 hour long scan during session 2
|
BOLD activation of frontostriatal regions in response to computer tasks performed during the fMRI Brian scan
|
1.5 hour long scan during session 2
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Cortisol Rating
Tidsramme: collected as part of 1.5 hour long scan during session 2
|
Saliva rating to be collected throughout the fMRI brain scan
|
collected as part of 1.5 hour long scan during session 2
|
Mood Rating
Tidsramme: collected as part of 1.5 hour long scan during session 2
|
Self-reported mood rating to be collected throughout the fMRI brain scan
|
collected as part of 1.5 hour long scan during session 2
|
Stress Reactivity Score
Tidsramme: Longitudinal, three time points (baseline, 3-month follow-up, 6-month follow-up)
|
Stress Reactivity Survey Item collected via smart-phone delivered ecological momentary assessment
|
Longitudinal, three time points (baseline, 3-month follow-up, 6-month follow-up)
|
Stress Reactive Rumination Score
Tidsramme: Longitudinal, three time points (baseline, 3-month follow-up, 6-month follow-up)
|
Stress Reactive Rumination Scale collected via smart-phone delivered ecological momentary assessment
|
Longitudinal, three time points (baseline, 3-month follow-up, 6-month follow-up)
|
Positive Affect Score
Tidsramme: Longitudinal, three time points (baseline, 3-month follow-up, 6-month follow-up)
|
Positive Affect Survey Items collected via smart-phone delivered ecological momentary assessment
|
Longitudinal, three time points (baseline, 3-month follow-up, 6-month follow-up)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Emily L Belleau, PhD, McLean Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- K23MH122668 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Major depressiv lidelse
-
Shalvata Mental Health CenterUkjentMAjor depressiv lidelseIsrael
-
Seasons Biotechnology (Taizhou) Co., Ltd.FullførtMajor depressiv lidelse (MDDIndia
-
Gangnam Severance HospitalFullførtMajor depressiv lidelse (MDD)Korea, Republikken
-
Seasons Biotechnology (Taizhou) Co., Ltd.FullførtMajor depressiv lidelse (MDD)India
-
Repurposed Therapeutics, Inc.Ukjent
-
GlaxoSmithKlineFullførtMajor depressiv lidelse (MDD)Forente stater
-
AccexibleRekrutteringMajor depressiv lidelse (MDD)Spania
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Har ikke rekruttert ennåMajor depressiv lidelse (MDD)
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RekrutteringMajor depressiv lidelse (MDD)Kina
-
Seasons Biotechnology (Taizhou) Co., Ltd.FullførtMajor depressiv lidelse (MDD)India
Kliniske studier på Computer Task Manipulation
-
Universidade Estadual do PiauÍFullførtSmerte | Ankelskader | OsteopatiBrasil
-
Riphah International UniversityRekrutteringKorsryggsmerter, postpartumPakistan
-
KU LeuvenAktiv, ikke rekrutterende
-
Yusra Medical and Dental CollegeFullført
-
Alabama Physical Therapy & AcupunctureUniversidad Rey Juan CarlosFullførtSacroiliac-ledddysfunksjonForente stater
-
Southern Methodist UniversityFullførtDepresjon | Understreke | Angst | KortisolForente stater
-
Spine and Sport, GeorgiaVirginia Commonwealth UniversityUkjent
-
University of Texas at AustinRekrutteringTraume | Posttraumatisk stresslidelseForente stater
-
Medical University of ViennaMedical University of GrazHar ikke rekruttert ennåHjerteutfall | Hemodynamisk måling | Ikke-invasivØsterrike